Drug Profile
Metoprolol/tesofensine - Saniona
Alternative Names: Tesofensine/metoprolol; TesometLatest Information Update: 24 Jan 2023
Price :
$50
*
At a glance
- Originator Saniona
- Class Antihyperglycaemics; Chlorobenzenes; Heterocyclic bicyclo compounds; Obesity therapies; Propanolamines; Small molecules
- Mechanism of Action Beta 1 adrenergic receptor antagonists; Biogenic monoamine uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Obesity; Prader-Willi syndrome; Type 2 diabetes mellitus
Most Recent Events
- 24 Jan 2023 Efficacy and adverse events data from a phase IIa trial in obesity presented at the 104th Annual Meeting of the Endocrine Society (ENDO-2022)
- 29 Mar 2022 Saniona suspended a phase II trial in Prader-Willi syndrome (In adults) in Spain, Italy, Sweden, United Kingdom, Australia, New Zealand, USA (PO) due to funding limitations (NCT05198362)
- 29 Mar 2022 Saniona temporarily paused a phase II trial in Obesity (In adolescents, In adults, In the elderly) in Spain, Italy, United Kingdom, Sweden, Australia, New Zealand, USA (PO)